Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 6Withdrawn 2Recruiting 2Not yet recruiting 2Active not recruiting 2Unknown 1Terminated 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 56Genitourinary 32Other hematologic neoplasm 16Plasma cell 2Dermatologic 2Thoracic 1Head & Neck 1Gynecologic 1CNS 1

Conditions

Melanoma 2Skin Neoplasms 1Drug-Related Side Effects and Adverse Reactions 1Colitis 1Carcinoma, Merkel Cell 1Carcinoma, Basal Cell 1

Interventions

pembrolizumab 72Nivolumab 49Ipilimumab 29Specimen Handling 15Magnetic Resonance Spectroscopy 15trametinib 14Biopsy 13dabrafenib 11cemiplimab 11avelumab 11binimetinib 10Radiotherapy 10Cyclophosphamide 10CTLA-4 Antigen 9fludarabine 7encorafenib 7atezolizumab 7Radiosurgery 7Immunoglobulin G 7Disulfides 7Cisplatin 7lenvatinib 6durvalumab 6Paclitaxel 6Carboplatin 6tislelizumab 5relatlimab 5fludarabine phosphate 5dostarlimab 5Pemetrexed 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Prednisone × Dermatologic × Clear all
NCT03816332 2026-04-30

Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers

National Cancer Institute (NCI)

Phase 1 Active not recruiting
12 enrolled 13 charts
Dermatologic

Carcinoma, Basal Cell, Melanoma, Carcinoma, Merkel Cell

NCT04305145 2026-01-29

Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis

Massachusetts General Hospital

Phase 2 Active not recruiting
42 enrolled
Dermatologic

Colitis, Melanoma, Skin Neoplasms, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡